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Introduction: The use of postoperative radiotherapy (PORT) after 
resection of non–small-cell lung cancer (NSCLC) is controversial, 
with some evidence suggesting a benefit in patients with N2 disease. 
We assessed lymph node ratio (LNR) as a predictor of PORT benefit.
Methods: By using the Surveillance, Epidemiology and End Results 
database, we analyzed resected, node-positive (N1–N2) NSCLC 
patients diagnosed between 1998 and 2009. LNR, (number of positive 
nodes/number of resected nodes) was categorized into four groups: 
LNR less than 12.5%, 12.5 to 24.9%, 25 to 49.9%, and 50% or more.
Results: Of 11,324 node-positive NSCLC patients identified, 6551 
(57.9%) had N1 disease. The LNR was prognostic for survival in 
the entire cohort and within each nodal stage. The median survival 
in LNR groups 1, 2, 3, and 4 was 43, 40, 30, and 23 months in N1 
disease and 40, 32, 27, and 22 months in N2 disease, respectively. 
PORT was associated with a worse survival on univariate analysis 
(hazard ratio [HR] =1.09; confidence interval [CI] 1.03–1.15; p = 
0.002) but no effect on multivariate analysis (HR = 0.96; CI 0.90–
1.02; p = 0.201). When analyzed by nodal stage, the benefit of PORT 
was limited to N2 disease (HR = 0.9; CI 0.84–0.99; p = 0.026) with 
no benefit in N1 disease (HR = 1.06; CI 0.97–1.15; p = 0.2). After 
stratifying by LNR, the survival benefit of PORT was limited to those 
with N2 disease and an LNR of 50% or more.
Conclusion: A high LNR is associated with a poorer survival in 
resected, node-positive NSCLC. The survival benefit associated with 
PORT in this disease seems to be limited to those with an LNR of 
50% or more. This warrants further investigation in other cohorts and 
prospective studies.
Key Words: Non–small-cell lung cancer, Postoperative radiotherapy, 
Lymph node ratio.
(J Thorac Oncol. 2013;8: 940-946)
Lung cancer is the second most common cancer diagnosed and the most common cause of cancer death in both sexes 
in the United States.1 Non–small-cell lung cancer (NSCLC) 
accounts for the majority of lung cancer cases. Treatment rec-
ommendations and prognosis are largely determined by the 
stage of cancer at diagnosis, with surgery typically recom-
mended in early stage tumors.
After surgical resection, a finding of involved lymph 
nodes (LNs) is a significant prognostic factor and provides an 
indication for adjuvant chemotherapy.2,3 The recommendation 
for adjuvant radiotherapy is more controversial. A previous 
meta-analysis suggested a detrimental effect of postoperative 
radiotherapy (PORT),4 but the relevance of this study is 
uncertain in light of recent advances in radiation techniques, 
and other nonrandomized studies have suggested that patients 
with advanced nodal disease (ie., N2 disease) may benefit from 
PORT.5,6 The American Joint Committee on Cancer Tumor 
Node Metastasis (TNM) lung cancer staging system classifies 
nodal stage based on the anatomical lymph node stations 
involved, irrespective of the absolute number of involved 
lymph nodes. Furthermore, it does not account for the number 
of LNs or LN stations examined, but recommendations that at 
least 6 to 10 lymph nodes or stations should be sampled have 
been suggested.7,8
The lymph node ratio (LNR), defined as the number of 
pathologically positive LNs divided by the number of LNs 
examined, has been proposed as a useful prognostic metric 
because it incorporates both the number of pathologically 
positive LNs and the number of LNs examined. The LNR 
has been shown to be prognostic in multiple malignancies, 
including breast cancer,9 colon cancer,10 and melanoma.11 It 
has been shown to be prognostic in NSCLC,12–15 but the major-
ity of these studies have included patients diagnosed in the 
era before positron emission tomography (PET) or integrated 
PET/computer tomography (PET/CT). Furthermore, the LNR 
has been shown to be predictive of PORT benefit in oral cavity 
squamous cell carcinoma (SCC).16
The purpose of this study was to further validate the 
LNR in the modern PET and PET/CT era and to evaluate its 
ability to predict the survival benefit of PORT in resected 
NSCLC.
MATERIALS And METhodS
The Surveillance, Epidemiology and End Results (SEER) 
program is a comprehensive source of population-based data 
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TABLE 1.  Demographics of All Resected, Node-Positive NSCLC Diagnosed between 1998 and 2009
All (N = 11,324)
LNR < 12.5%  
N = 2521 (22%)
LNR12.5–24.9,% 
N = 2869 (25%)
LNR 25–49.9% 
N = 3042 (27%)
LNR > = 50%  
N = 2892 (26%) p
Age (yr) 0.25
 <50 890 (7.9%) 180 (7.1%)) 229 (8.0%) 238 (7.8%) 243 (8.4%)
 50–59 2556 (22.6%) 560 (22.2%) 642 (22.4%) 729 (24.0%) 625 (21.6%)
 60–69 3759 (33.2%) 863 (34.2%) 974 (34.0%) 948 (31.2%) 974 (33.7%)
 70–79 3370 (30%) 754 (29.9%) 827 (28.8%) 935 (30.7%) 854 (29.5%)
 80+ 749 (6.6%) 164 (6.5%) 197 (6.9%) 192 (6.3%) 196 (6.8%)
Sex 0.003
 Women 5195 (45.9%) 1090 (43%) 1292 (45%) 1430 (47%) 1383 (48%)
Year of diagnosis <0.001
 1998–2000 1997 (17.6%) 391 (15.5%) 428 (14.9%) 519 (17.1%) 659 (22.8%)
 2001–2003 2996 (26.5%) 592 (23.5%) 779 (27.2%) 799 (26.3%) 826 (28.6%)
 2004–2006 3127 (27.6%) 707 (28.0%) 797 (27.8%) 874 (28.7%) 749 (25.9%)
 2007–2009 3204 (28.3%) 831 (33%) 865 (30.2%) 850 (27.9%) 658 (22.8%)
Racea <0.001
 White 9462 (83.7%) 2189 (86.9%) 2393 (83.5%) 2520 (83%) 2360 (81.6%)
 Black 1000 (8.8%) 178 (7.1%) 268 (9.4%) 290 (9.6%) 264 (9.1%)
 Other 850 (7.5%) 151 (6%) 205 (7.2%) 227 (7.5%) 267 (9.2%)
Gradeb 0.52
 1 494 (4.7%) 103 (4.3%) 133 (4.9%) 137 (4.8%) 121 (4.5%)
 2 4244 (40%) 940 (39.6%) 1057 (39.2%) 1140 (40%) 1107 (41.1%)
 3 5452 (51.3%) 1221 (51.5%) 1385 (51.3%) 1473 (51.5%) 1373 (50.9%)
 4 434 (4.1%) 108 (4.6%) 123 (4.6%) 108 (3.8%) 95 (3.5%)
Histology <0.001
 NSCLC, NOS 584 (5.2%) 134 (5.3%) 154 (5.4%) 161 (5.3%) 135 (4.7%)
 SCC 3460 (30.6%) 959 (38%) 985 (34.3%) 896 (29.5%) 620 (24.1%)
 Adenocarcinoma 4960 (43.8%) 934 (37.1%) 1177 (41%) 1357 (44.6%) 1492 (51.6%)
 BAC 574 (5.1%) 105 (4.2%) 134 (4.7%) 170 (5.6%) 165 (5.7%)
 Adeno with mixed subtypes 1175 (10.4%) 240 (9.5%) 267 (9.3%) 316 (10.4%) 352 (12.2%)
 Large-cell 571 (5%) 149 (5.9%) 152 (5%) 142 (4.7%) 128 (4.4%)
Lateralityc 0.13
 Right 6102 (53.9%) 1348 (53.5%) 1532 (53.4%) 1609 (53%) 1613 (55.8%)
Surgeryd <0.001
 Lobectomy 9168 (81.1%) 1928 (76.6%) 2306 (80.4%) 2488 (81.9%) 2446 (84.8%)
 Pneumonectomy 2140 (18.9%) 590 (23.4%) 561 (19.6%) 551 (18.1%) 438 (15.2%)
T stagee 0.001
 1 2759 (26.1%) 591 (24.9%) 707 (26.2%) 744 (26.2%) 717 (26.9%)
 2 5757 (54.4%) 1328 (56%) 1490 (55.1%) 1552 (54.7%) 1387 (52.1%)
 3 796 (7.5%) 190 (8%) 220 (8.1%) 209 (7.4%) 177 (6.7%)
 4 1263 (11.9%) 263 (11.1%) 285 (10.6%) 335 (11.8%) 380 (14.3%)
N-stage <0.001
 1 6551 (57.9%) 1800 (71.4%) 1793 (62.5%) 1660 (54.6%) 1298 (44.9%)
 2 4773 (42.2%) 721 (28.6%) 1076 (37.5%) 1382 (45.4%) 1594 (55.1%)
RTf <0.001
 No PORT 7256 (70.7%) 1858 (81.3%) 1934 (74.2%) 1861 (67.4%) 1603 (61.3%)
 PORT 3011 (29.3%) 428 (18.7%) 672 (25.8%) 900 (32.6%) 1011 (38.7%)
LN examined <0.001
 <10 5876 (51.9%) 240 (2.1%) 1527 (13.5%) 1865 (16.5%) 2244 (19.8%)
 > = 10 5448 (48.1%) 2281 (20.1%) 1342 (11.9%) 1177 (10.4%) 648 (5.7%)
aData on race were missing for 12 patients
bGrade was available for 10,624 patients.
cLaterality was available for 11,315 patients.
dData about type of surgery were available for 11,308 patients.
eT-stage was available for 10,575 patients.
fRT data were available for 10,267 patients.
LN, lymph node; LNR, lymph node ratio; NSCLC, non–small-cell lung cancer; NOS, not otherwise specified; BAC, bronchoalveolar carcinoma; RT, radiotherapy; PORT, 
postoperative radiotherapy; SCC, squamous cell carcinoma.
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in the United States, which includes patient demographics, 
primary tumor site and histology, stage of cancer at the time of 
diagnosis, and surgical and/or radiation treatment as part of the 
first treatment. In 2001, the database was expanded to include 
new regions of the United States, covering approximately 26% 
of the population. Inclusion criteria were patients registered 
within the SEER 18 database between 1998 and 2009, with 
a single cancer diagnosis of NSCLC who underwent surgical 
resection (defined as at least a lobectomy), with at least one 
lymph node involved, and a TNM nodal stage of N1 or N2. 
The stage of these patients recorded in SEER is the patho-
logical TNM stage. The histologic subtypes included were: 
NSCLC, NOS; large-cell carcinoma (large-cell carcinoma, 
NOS, large-cell neuroendocrine carcinoma, giant cell carci-
noma); SCC (papillary squamous cell, SCC NOS, SCC kera-
tinizing NOS, SCC large-cell nonkeratinizing, SCC small-cell 
nonkeratinizing); adenocarcinoma (AC) (AC NOS); AC with 
mixed subtypes (AC with mixed subtype, papillary AC NOS, 
clear-cell AC NOS, mucinous producing AC, signet ring cell 
carcinoma, adenosquamous); and bronchoalveolar carcinoma 
(BAC, BAC nonmucinous, BAC mucinous, BAC mucinous 
and nonmucinous).
LNR categories were divided into four similar-sized 
groups based on quartiles: group 1 was defined as LNR less 
than 12.5%, group 2 as LNR 12.5 to 24.9%, group 3 as LNR 
25 to 49.9% and group 4 as LNR 50% or more. Staging was 
based on the American Joint Committee of Cancer 6th edition 
TNM staging as extracted from the SEER database. The num-
ber of LNs examined was divided into two groups: less than 
10 LNs and 10 LNs or more because the removal of 10 LNs 
has been associated with the highest median survival.8
Statistical analyses were performed using the Stata 
Statistical package (version IC 11.1; Statacorp, College 
Station, TX). Correlations between categorical variables were 
analyzed with χ2tests. Overall survival (OS) from date of diag-
nosis was calculated using the Kaplan–Meier method. Patients 
with missing data were excluded from the multivariate analysis. 
A two-sided p value less than 0.05 was considered statistically 
significant. (survival months changed from 0 to 0.5)
RESULTS
A total of 11,324 NSCLC patients were identified. The 
median age at diagnosis was 66 years among the entire cohort 
and in each LNR group. Demographics, tumor characteris-
tics, and the use of PORT are summarized in Table 1, for all 
patients and according to LNR. The distribution of LNR is 
illustrated in Figure 1.
Factors associated with a higher LNR included women, 
diagnosis in earlier years, nonwhites, AC compared with 
SCC, right-sided tumors, lobectomy, a higher T-stage, a higher 
N-stage, and examination of less than 10 LNs. The use of 
PORT was more common in patients with a high LNR.
The median follow-up of all patients was 21 months 
(range, 0.5–124) and of those alive was 33 months (range, 
0.5–143). Variables associated with OS on univariate and mul-
tivariate analysis are summarized in Table 2. The TNM N-stage 
was significantly associated with OS. The median survival of 
N1 and N2 disease was 33 and 27 months, respectively, and 
the 5-year survival of N1 and N2 disease was 33 and 27%, 
respectively. LNR was able to provide further prognostic value 
within each nodal stage, both for OS (Fig. 2) and cancer-spe-
cific survival (Supplementary Fig. 1, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A411). The median sur-
vival in LNR groups 1, 2, 3, and 4 was 43, 40, 30, and 23 
months in N1 disease and 40, 32, 27, and 22 months in N2 
disease, respectively.
Among all patients PORT was associated with a worse 
survival outcome on univariate analysis (hazard ratio [HR] = 
1.09; confidence interval [CI] 1.03–1.15; p = 0.002) but no effect 
on multivariate analysis (HR = 0.96; CI 0.90–1.02; p = 0.201). 
When analysed by nodal stage, the benefit of PORT was limited 
to N2 disease (HR = 0.91; CI 0.84–0.99; p = 0.026), with no 
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TABLE 2.   Univariate and Multivariate Analysis for Overall Survival
Univariate Multivariatea
HR (CI) p HR (CI) p
Age (yr)
 <50 1 1
 50–59 1.15 (1.04–1.29) 0.008 1.19 (1.05–1.35) 0.007
 60–69 1.33 (1.20–1.47) <0.001 1.41 (1.25–1.59) <0.001
 70–79 1.76 (1.59–1.95) <0.001 1.96 (1.74–2.21) <0.001
 80+ 2.11 (1.86–2.40) <0.001 2.38 (2.05–2.76) <0.001
Sex
 Women 1 1
 Men 1.29 (1.23–1.35) <0.001 1.25 (1.18–1.33) <0.001
Year of diagnosis
 1998–2000 1 1
 2001–2003 0.91 (0.85–0.97) 0.003 0.96 (0.89–1.04) 0.297
 2004–2006 0.75 (0.70–0.80) <0.001 0.79 (0.73–0.85) <0.001
 2007–2009 0.67 (0.62–0.73) <0.001 0.72 (0.65–0.79) <0.001
Race
 White 1 1
 Black 0.99 (0.91–1.08) 0.82 1.04 (0.95–1.15) 0.241
 Other 0.90 (0.82–0.98) 0.019 0.89 (0.80–0.98) 0.024
Grade
 1 1 1
 2 1.11 (0.98–1.26) 0.108 1.04 (0.90–1.19) 0.624
 3 1.29 (1.14–1.46) <0.001 1.20 (1.04–1.38) 0.010
 4 1.37 (1.16–1.61) <0.001 1.19 (0.97–1.46) 0.105
Histology
 SCC 1 1
 NSCLC, NOS 0.97 (0.86–1.08) 0.539 1.11 (0.97–1.28) 0.146
 Adenocarcinoma 0.91 (0.86–0.97) 0.002 1.01 (0.94–1.08) 0.867
 BAC 0.88 (0.78–0.98) 0.019 0.96 (0.84–1.10) 0.531
 Adeno with mixed subtypes 0.91 (0.83–0.99) 0.029 0.97 (0.87–1.07) 0.503
 Large-cell 1.13 (1.01–1.26) 0.03 1.08 (0.93–1.27) 0.316
Laterality
 Right 1 1
 Left 0.98 (0.93–1.03) 0.406 0.92 (0.87–0.97) 0.002
Surgery
 Lobectomy 1 1
 Pneumonectomy 1.23 (1.21–1.35) <0.001 1.23 (1.14–1.32) <0.001
T-stage
 1 1 1
 2 1.39 (1.31–1.48) <0.001 1.35 (1.26–1.44) <0.001
 3 1.84 (1.67–2.03) <0.001 1.83 (1.64–2.04) <0.001
 4 1.96 (1.80–2.13) <0.001 1.81 (1.65–1.99) <0.001
N-stage
 1 1 1
 2 1.17 (1.12–1.23) <0.001 1.16 (1.09–1.23) <0.001
RT
 No PORT 1 1
 PORT 1.09 (1.03–1.15) 0.002 0.96 (0.90–1.02) 0.201
LN examined
 <10 1 1
 > = 10 0.88 (0.84–0.92) <0.001 0.99 (0.93–1.06) 0.743
LNR
 <12.5% 1 1
 12.5–24.9 1.09 (1.01–1.18) 0.019 1.09 (1.0–1.20) 0.05
 25–49.9% 1.38 (1.29–1.48) <0.001 1.42 (1.30–1.55) <0.001
 > = 50% 1.73 (1.61–1.85) <0.001 1.78 (1.62–1.95) <0.001
aOn the basis of 9897 patients who had all data available.
BAC, bronchoalveolar carcinoma CI, confidence interval; HR, hazard ratio; LN, lymph node; LNR, lymph node ratio; NSCLC, non–small-cell lung cancer; NOS, not otherwise 
specified; PORT, postoperative radiotherapy; RT, radiotherapy; SCC, squamous cell carcinoma.
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stratifying by LNR, the benefit of RT was limited to those with 
N2 disease and an LNR of 50% or more for OS (Table 3) and 
cancer-specific survival (Supplementary Table 1, Supplementary 
Digital Content 2, http://links.lww.com/JTO/A412).
The use of PORT has decreased over time, with 43% of 
patients receiving PORT between 1998 and 2000 compared 
with 21% receiving PORT between 2007 and 2009, includ-
ing in N2 disease (54 versus 33%, respectively). Furthermore, 
the use of PORT has significantly decreased, in patients with 
N2 disease and an LNR of 50% or more, from 54%, between 
1998 and 2000, to 41% between 2007 and 2009 (p < 0.001), 
respectively.
A repeat analysis limited to patients diagnosed since 
2003, when PET was performed among the majority of early 
stage NSCLC,17 confirmed a similar prognostic and predictive 
value of LNR (data not shown).
dISCUSSIon
In this large population-based study, we demonstrate that 
LNR has prognostic significance, in addition to the standard 
TNM nodal staging in resected NSCLC. Furthermore, these 
data indicate that the benefit of PORT in resected NSCLC may 
be limited to N2 disease with an LNR of 50% or more.
Accurate staging of lung cancer is essential. It impacts 
on selecting the appropriate treatment, allows prognostic 
information to be conveyed to patients and their families, and 
facilitates communication between health care professionals, 
including the appropriate stratification in clinical trials. We 
have confirmed that the LNR provides additional, and possi-
bly even more accurate, prognostic information than the cur-
rent nodal staging. This is consistent with previous reports in 
NSCLC.12–15
In contrast to most previous reports, we limited our 
study to patients diagnosed since 1998, after PET and inte-
grated PET/CT was introduced into clinical practice.18 The use 
of PET, and particularly integrated PET/CT, is known to result 
in more accurate nodal staging of NSCLC19,20 and reduces the 
number of thoracotomies and futile thoracotomies.21 It has 
been shown that the majority of early stage NSCLC patients, 
who are Medicare beneficiaries in the United States have had 
a PET since 2003.17 Our results are therefore, relevant with 
current modern staging investigations. Furthermore, a repeat 
analysis of patients diagnosed since 2003 confirmed the prog-
nostic and predictive value of LNR.
There is no consensus regarding the benefit of PORT 
in resected NSCLC. The risk of local recurrence is generally 
lower with PORT,22 but studies reporting a detrimental effect on 
survival have discouraged the use of PORT. This is reflected in 
our study with the decrease in use of PORT over time, even in 
those patients who potentially stand to benefit from PORT, such 
as N2 disease and a high LNR. Currently, the Lung Adjuvant 
Radiotherapy (Lung ART) trial is prospectively evaluating the 







N1 1.06 (0.97–1.15) 0.20
 LNR < 12.5% (n = 1508) 1.08 (0.88–1.32) 0.47
 LNR12.5–24.9% (n = 1494) 1.14 (0.96–1.35) 0.15
 LNR 25–49.9% (n = 1384) 1.11 (0.95–1.30) 0.20
 LNR ≥ 50% (n = 1063) 0.94 (0.81–1.11) 0.477
N2 0.86 (0.79–0.94) 0.001
 LNR < 12.5% (n = 528) 0.94 (0.71–1.23) 0.632
 LNR12.5–24.9% (n = 829) 0.94 (0.77–1.15) 0.55
 LNR 25–49.9% (n = 1042) 0.90 (0.76–1.06) 0.212
 LNR ≥ 50% (n = 1197) 0.78 (0.67–0.90) 0.001
LNR, lymph node ratio.
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Why is a high LNR predictive of the benefit of PORT? 
One plausible explanation is that the risk of locoregional 
recurrence may be higher in those with a high LNR and may 
define a group in whom the benefit of PORT outweighs the 
toxicity. There are data supporting this relationship between 
LNR and locoregional recurrence in breast23 and rectal can-
cer,24 but this has not been reported in NSCLC.
Another possible explanation is that the LNR may 
reflect the body’s immune system and the tumor-host inter-
action. It is well documented that infiltration of lymphocytes 
occurs within tumors and has been associated with prognosis 
in many tumor types,25 including NSCLC.26 Furthermore, the 
presence of CD8+ tumor-infiltrating lymphocytes is associ-
ated with the absence of lymph node metastases in cervical 
cancer.27 The LNR may, therefore, serve as a marker of the 
tumor-host interaction and provide prognostic information. 
Furthermore, the value of the LNR as a predictor of radio-
therapy (RT) benefit may also be a result of the interaction 
between the immune system and RT.28
An additional explanation may be that PORT may com-
pensate for a suboptimal or inadequate surgical resection, as 
has been suggested in gastric cancer.29 A definition of a com-
plete resection in lung cancer surgery has been developed,30 
and it is known that microscopic positive margins are associ-
ated with a significantly poorer prognosis.31 However, the opti-
mal extent of lymph node resection is unclear as is its effect on 
survival. Given the LNR is intrinsically affected by the num-
ber of LNs removed, the adequacy of lymph node dissection 
or sampling will affect the LNR. The SEER data do not record 
the quality and/or completeness of resection. To minimize 
this confounder, we included the number of LNs removed in 
our multivariate analysis and found this to be nonsignificant. 
This finding suggests the LNR may have a prognostic and pre-
dictive value beyond being a surrogate marker for adequate 
surgery.
Limitations of this study include the retrospective nature 
and the lack of information regarding the indications for and 
techniques of RT used. Other confounding factors lacking in 
SEER include patients’ comorbidities, performance status, 
the use of chemotherapy, and as mentioned, the completeness 
of surgical resection and lymph node dissection. There are 
also data suggesting that there are some inaccuracies in the 
reporting of RT use in the SEER database in breast cancer 
patients,32 though whether this is true for lung cancer patients 
is unknown. The large size of the study’s population and the 
fact that a CT-based RT planning was common after 1998 
minimizes some of these limitations.
In conclusion, our study validates LNR as a significant 
prognostic factor in resected NSCLC. Importantly, these data 
indicate that LNR may predict which one of the patients ben-
efit from PORT. The predictive value of LNR requires valida-
tion in a prospective study.
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